ArticleEuropean heart journal. Digital health2026
Optimizing diagnostic resource use in suspected chronic coronary syndrome: pre-test probability and acoustic CAD rule-out in the FILTER-SCAD trial.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The FILTER-SCAD trial combined pre-test-probability (PTP) and the FDA-cleared coronary artery disease (CAD)-Score System to guide and improve deferred testing in suspected chronic coronary syndrome (CCS). However, adherence to the recommended strategy was low, with fewer than one-fourth of patients deferred. This study evaluates the potential of a PTP- and CAD-score-based deferral strategy on diagnostic resource consumption and clinical outcomes. Methods and results: This observational post-hoc analysis included 1002 patients from the FILTER-SCAD intervention arm. Deferred testing was recommended for PTP ≤5% and/or CAD-score ≤20. We calculated the number of potentially deferred tests and clinical outcomes, including significant CAD and major adverse cardiac events (MACE). A deferred testing strategy could nearly double the number of safely deferred tests, reducing overall diagnostic test ( Conclusion: A strategy incorporating PTP and CAD-score can safely reduce unnecessary testing in low-likelihood CCS patients, optimizing resource use without compromising outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.